Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 15/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | PRMT5 | O14744 | 5/20 | 0.36 |
| ▸ | WDR77 | Q9BQA1 | 5/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25312643 | 1.00 | PARP1 (0.40) | PARP1HDAC6PRMT5WDR77 | |
| SCHEMBL30132752 | 1.00 | PARP1 (0.40) | PARP1HDAC6PRMT5WDR77 | |
| SCHEMBL25890288 | 0.94 | PARP1 (0.47) | PARP1 | |
| SCHEMBL25890286 | 0.94 | PARP1 (0.47) | PARP1 | |
| SCHEMBL25890280 | 0.93 | PARP1 (0.43) | PARP1HDAC6PRMT5WDR77 | |
| SCHEMBL29565341 | 0.93 | PARP1 (0.43) | PARP1HDAC6PRMT5WDR77 | |
| SCHEMBL25315024 | 0.93 | PARP1 (0.43) | PARP1HDAC6PRMT5WDR77 | |
| SCHEMBL25316173 | 0.93 | PARP1 (0.40) | PARP1HDAC6PRMT5WDR77 | |
| SCHEMBL30132750 | 0.93 | PARP1 (0.40) | PARP1HDAC6PRMT5WDR77 | |
| SCHEMBL25312615 | 0.90 | PARP1 (0.43) | PARP1PRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234938-A1 | NOVEL COMPOUNDS USEFUL AS POLY(ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS | RHIZEN PHARMACEUTICALS AG (CH) | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234938-A1 | NOVEL COMPOUNDS USEFUL AS POLY(ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS | PARP1, PARP2, PARP3 | PARP1 1/4885HDAC6 202/4885PRMT5 1563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.